Symptomatic Bradycardia Due to Alectinib in a Patient with Advanced Stage of NSCLC

• Glavni autori: Ceva Wicaksono Pitoyo (Autor), Cleopas Martin Rumende (Autor), Anindita Kartika Wiraputri (Autor), Fatira Ratri Audita (Autor)
• Format: Knjiga
• Izdano: Interna Publishing, 2022-04-01T00:00:00Z.
• Teme: article
• Online pristup: Connect to this object online.

Alectinib is one of the targeted therapies commonly given to patients with advanced non-small cell lung cancer (NSCLC) with mutations in the ALK gene. The most common adverse effects of alectinib are fatigue, constipation, edema, myalgia and anemia. Meanwhile, bradycardia was reported as a very comm...